Jiangsu Hengrui Pharmaceuticals posts 13.7% revenue growth, 24.5% profit surge, and receives JPMorgan Overweight upgrade amid China’s new drug‑insurance policy.

Jiangsu Hengrui Pharmaceuticals Co Ltd has reported robust growth in its latest earnings, with a 13.4% increase in revenue and a 43.9% rise in net income, leading to an upgrade by JPMorgan to an ‘Overweight’ rating, citing sustained revenue momentum…